PeterWeidenMD
Psychiatry • North Waltham, MANeuropsychiatry, Psychopharmacology, Clinical Pharmacology
Clinical Professor of Psychiatry (Voluntary) Renaissance School of Medicine at Stony Brook University
Dr. Weiden is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
852 Winter Street
North Waltham, MA 02451Phone+1 917-701-7484
Education & Training
Columbia University Mailman School of Public HealthMS, Psychiatric Epidemiology, 1996 - 1998
New York Presbyterian Hospital (Cornell Campus)Residency, Psychiatry, 1981 - 1985
Stony Brook University Health Sciences Center School of MedicineClass of 1981
Certifications & Licensure
NY State Medical License 1982 - 2025
IL State Medical License 2007 - 2020- American Board of Psychiatry and Neurology Psychiatry
Awards, Honors, & Recognition
- Top Doctors: New York Metro Area Castle Connolly, 2002-2006
Clinical Trials
- PREvent First Episode Relapse (PREFER) Start of enrollment: 2004 Nov 01
Publications & Presentations
PubMed
- Initiating Aripiprazole Lauroxil: Post Hoc Analysis of Safety and Tolerability of 1-Day and 21-Day Regimens.Roger W Sommi, Stephen R Saklad, Peter J Weiden, Daniel Still, Meihua Wang
The Journal of Clinical Psychiatry. 2024-08-12 - 22 citationsSafety and tolerability of KarXT (xanomeline-trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia.Christoph U Correll, Angel S Angelov, Andrew C Miller, Peter J Weiden, Stephen K Brannan
Schizophrenia. 2022-12-03 - 8 citationsImpaired insight in schizophrenia: impact on patient-reported and physician-reported outcome measures in a randomized controlled trial.Paul H Lysaker, Peter J Weiden, Xiaowu Sun, Amy K O'Sullivan, Joseph P McEvoy
BMC Psychiatry. 2022-08-28
Journal Articles
- Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic. Trends in Pharmacological Sciences (2022) https://doi.org/10.1016/j.tips.2022.09.006Yohn SE, Weiden PJ, Felder CC & Stahl SM, Trends in Pharmacological Sciences (2022), 12/1/2022
- Antipsychotic Efficacy of KarXT (Xanomeline− Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, ...Weiden PJ, Breier A, Kavanagh S, Miller AC, Brannan SK, & Paul SM, The Journal of Clinical Psychiatry, 83(3), 40913. (2022), 9/1/2022
Press Mentions
Deep Sleep “Therapy” in Australia in the 1960s & ’70s: Could Something like This Happen Today?August 27th, 2020
Neuroleptic and Anti-Depressant Drugs: Akathisia, Suicide and ViolenceNovember 8th, 2016- How Clinicians Can Brush up on Emerging Schizophrenia DrugsOctober 11th, 2023
Professional Memberships
- Fellow
- Schizophrenia International Research SocietyMember
- American Society of Clinical PsychopharmacologyMember
- The International Society for CNS Clinical Trials and Methodology (ISCTM) Member
External Links
- Linked Inhttps://www.linkedin.com/in/peter-weiden-0075a513b/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
